The stock of Plus Therapeutics Inc (PSTV) has seen a 88.53% increase in the past week, with a 124.79% gain in the past month, and a 16.37% flourish in the past quarter. The volatility ratio for the week is 18.96%, and the volatility levels for the past 30 days are at 13.50% for PSTV. The simple moving average for the past 20 days is 87.32% for PSTV’s stock, with a -14.79% simple moving average for the past 200 days.

Is It Worth Investing in Plus Therapeutics Inc (NASDAQ: PSTV) Right Now?

The 36-month beta value for PSTV is also noteworthy at 0.75. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”

Top 5 Artificial Intelligence Stocks to Buy for 2024

By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it. According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."

Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"


The average price estimated by analysts for PSTV is $17.50, which is $14.87 above than the current price. The public float for PSTV is 4.42M, and at present, short sellers hold a 0.90% of that float. The average trading volume of PSTV on November 20, 2023 was 658.00K shares.

PSTV) stock’s latest price update

The stock price of Plus Therapeutics Inc (NASDAQ: PSTV) has jumped by 20.64 compared to previous close of 2.18. Despite this, the company has seen a gain of 88.53% in its stock price over the last five trading days. PennyStocks reported 2023-11-03 that Penny stocks, also known as micro-cap equities or stocks under $5 per share, offer investors affordable opportunities. This is to buy shares in emerging small companies early before potential growth and upside.

Analysts’ Opinion of PSTV

Many brokerage firms have already submitted their reports for PSTV stocks, with Ladenburg Thalmann repeating the rating for PSTV by listing it as a “Buy.” The predicted price for PSTV in the upcoming period, according to Ladenburg Thalmann is $8 based on the research report published on January 25, 2021 of the previous year 2021.

PSTV Trading at 97.98% from the 50-Day Moving Average

After a stumble in the market that brought PSTV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.93% of loss for the given period.

Volatility was left at 13.50%, however, over the last 30 days, the volatility rate increased by 18.96%, as shares surge +128.70% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +90.58% upper at present.

During the last 5 trading sessions, PSTV rose by +88.53%, which changed the moving average for the period of 200-days by -57.24% in comparison to the 20-day moving average, which settled at $1.48. In addition, Plus Therapeutics Inc saw -44.69% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at PSTV starting from Lenk Robert P, who purchase 1,000 shares at the price of $1.95 back on Nov 16. After this action, Lenk Robert P now owns 25,160 shares of Plus Therapeutics Inc, valued at $1,950 using the latest closing price.

Lenk Robert P, the Director of Plus Therapeutics Inc, purchase 1,000 shares at $1.77 during a trade that took place back on Nov 15, which means that Lenk Robert P is holding 24,160 shares at $1,770 based on the most recent closing price.

Stock Fundamentals for PSTV

Current profitability levels for the company are sitting at:

The net margin for Plus Therapeutics Inc stands at -9051.34. The total capital return value is set at -131.77, while invested capital returns managed to touch -153.12. Equity return is now at value -216.23, with -83.36 for asset returns.

Based on Plus Therapeutics Inc (PSTV), the company’s capital structure generated 87.59 points at debt to equity in total, while total debt to capital is 46.69. Total debt to assets is 23.65, with long-term debt to equity ratio resting at 60.93. Finally, the long-term debt to capital ratio is 32.48.

When we switch over and look at the enterprise to sales, we see a ratio of -0.15, with the company’s debt to enterprise value settled at -1.36. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.84.


In summary, Plus Therapeutics Inc (PSTV) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.